Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Adamas Pharma (ADMS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Adamas Pharmaceuticals Inc's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Adamas Pharmaceuticals Inc historical data, for real-time data please try another search
8.220 +0.000    +0.00%
23/11 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 8.230 / 8.300
  • Day's Range: 8.180 - 8.250
Adamas Pharmaceuticals Inc 8.220 +0.000 +0.00%

Adamas Pharma Company Profile

 
Get an in-depth profile of Adamas Pharma, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

138

Equity Type

ORD

As of November 24, 2021, Adamas Pharmaceuticals, Inc. was acquired by Supernus Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer’s type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Contact Information

Address 1900 Powell Street Suite 1000
EmeryVille, 94608
United States
Phone 510 450 3500
Fax 510 428 0519
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ADMS Comments

Write your thoughts about Adamas Pharma
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
PlanetApe Ape
PlanetApe Ape Oct 11, 2021 9:01AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Juat in: Supernus Pharma To Acquire Adamas Pharma For Total Consideration Up To $9.10/shr
SS SS
SS SS Jun 05, 2020 12:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Adamas ? is it worths to entry ?
Raffael Cavaliere
Raffael Cavaliere Sep 19, 2018 12:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pressure to discuss the sale of the company seems to be growing up. https://chn.ge/2OEI2kD
Joel Hanson
Joel Hanson Nov 17, 2016 11:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
All 8 analyst covering ADMS recommend "buy." The average target price consensus for the next 12 months is $34 which is 110% ROI at its current price of $16.16.
Joe Mingoia
Joe Mingoia Nov 17, 2016 11:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
revenue is going to increase exponentially once this parkinsons drug gets out in circulation in January 18 .. that will be good for top and bottom line numbers come earning seasons.$$$$$. and mist of all definitely great for patients suffering.
Krypto Nite
Krypto Nite Nov 17, 2016 11:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Huh, so price targets me nothing. The more you know (it's not getting anywhere near $30 in the next 3 months)
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email